Supplementary Figure 1 from PI3K–mTOR Pathway Inhibition Exhibits Efficacy Against High-grade Glioma in Clinically Relevant Mouse Models
Fan Lin, Olaf van Tellingen(The Netherlands Cancer Institute), Mark C. de Gooijer(Manchester Academic Health Science Centre), Tom Würdinger(Harvard University), G. Chandrasekaran(Pondicherry University), Jos H. Beijnen(The Netherlands Cancer Institute), Levi C.M. Buil(Cancer Genomics Centre), Nishita Thota(The Netherlands Cancer Institute), Diana Hanekamp(Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital), Rolf W. Sparidans(Slotervaartziekenhuis)
Cited by 0
Related Papers
Overcoming the blood–brain tumor barrier for effective glioblastoma treatment
|Drug Resistance Updates|2015|1k
A phase I study of the natural killer T-cell ligand alpha-galactosylceramide (KRN7000) in patients with solid tumors.
|PubMed|2002|507
Clinical Pharmacokinetics of Cyclophosphamide
|Clinical Pharmacokinetics|2005|451
DPYD genotype-guided dose individualisation of fluoropyrimidine therapy in patients with cancer: a prospective safety analysis
|The Lancet Oncology|2018|419
Pharmacokinetics of paclitaxel and metabolites in a randomized comparative study in platinum-pretreated ovarian cancer patients.
|Journal of Clinical Oncology|1993|313